Fulgent GeneticsFLGT +2.67%59 Current Ratio is 5.31 as of Mar. 2026, which is 20% below its 10-year median of 6.64. GuruFocus rates FLGT with a GF Score™ of 59/100 and a GF Value™ of $23.99 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Fulgent Genetics ranks better than 87.85% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Fulgent Genetics's current ratio for the quarter that ended in Mar. 2026 was 5.31.
Fulgent Genetics has a current ratio of 5.31. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Fulgent Genetics's Current Ratio or its related term are showing as below:
FLGT'
s Current Ratio Range Over the Past 10 Years
Min: 3.35 Med: 6.64 Max: 18.2
Current: 5.31
During the past 12 years, Fulgent Genetics's highest Current Ratio was 18.20. The lowest was 3.35. And the median was 6.64.
FLGT's Current Ratio is ranked better than 87.85% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.99
vs FLGT: 5.31
Fulgent Genetics (NAS:FLGT) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Fulgent Genetics Current Ratio Related Terms
Fulgent Genetics Current Ratio Historical Data
* Premium members only.
The historical data trend for Fulgent Genetics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FLGT vs MYGN, CSTL, BDSX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Fulgent Genetics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fulgent Genetics Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Fulgent Genetics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fulgent Genetics (FLGT) has a Current Ratio of 5.31 as of Mar. 2026. This is 20% below median its historical median of 6.64. Over the past decade, Fulgent Genetics' Current Ratio has ranged from 3.35 to 18.20. According to the industry distribution chart, Fulgent Genetics ranks #26 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 12.1%.
Is Fulgent Genetics' Current Ratio too high?
Fulgent Genetics' current Current Ratio of 5.31 is 20% below median its 10-year median of 6.64. Over the past 10 years, this metric has ranged from a low of 3.35 to a high of 18.20. The Medical Diagnostics & Research industry median Current Ratio is 1.99. Fulgent Genetics' value of 5.31 is 166.8% above this industry median. Based on the distribution chart, Fulgent Genetics ranks #26 out of 214 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Fulgent Genetics has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Current Ratio compare to MYGN and CSTL?
According to the Medical Diagnostics & Research industry distribution chart, Fulgent Genetics ranks #26 out of 214 companies for Current Ratio. This places Fulgent Genetics in the top 12% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.99. Fulgent Genetics' value of 5.31 is 166.8% above this benchmark. Historically, Fulgent Genetics' own Current Ratio has ranged from 3.35 to 18.20 over the past decade. While the company's 10-year median is 6.64 vs. the industry median of 1.99, Fulgent Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.99, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fulgent Genetics's current Current Ratio of 5.31 is 166.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fulgent Genetics's current Current Ratio is 5.31, which is 20% below median its own 10-year median of 6.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Based on GuruFocus' analysis, Fulgent Genetics (FLGT) is currently considered Modestly Undervalued. The stock's GF Value™ is $23.99, compared to a current price of $19.96 — trading 16.8% below its estimated fair value. The current Current Ratio is 5.31, which is 20% below median its 10-year median of 6.64 and 166.8% above the Medical Diagnostics & Research industry median of 1.99. Fulgent Genetics' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Fulgent Genetics (FLGT), the current Current Ratio is 5.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fulgent Genetics (FLGT) Overvalued in 2026?
Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued.
The current stock price of $19.96 is trading 16.8% below its estimated GF Value™ of $23.99.
GuruFocus considers Fulgent Genetics to be Modestly Undervalued.
Key valuation signals for FLGT:
Current Ratio: 5.31 (20% below median its 10-year median of 6.64)
GF Value™: $23.99 vs. price of $19.96 (16.8% below fair value)
Industry Position: 166.8% above the Medical Diagnostics & Research median (#26 of 214)
No single metric tells the full story. See the FLGT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
59GF Score
Get the complete analysis for FLGT
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FLGT has been successfully added to your 
